DRDO 2DG medicine: MSN Labs inks licencing pact with DRDO for Covid-19 drug 2-DG | India Business News – Times of India
[ad_1]
HYDERABAD: Pharma player MSN Laboratories Pvt Ltd (MSN) has entered into a license agreement with the Defence Research & Development Organisation (DRDO) for the manufacturing, distribution and marketing of Covid-19 drug 2-Deoxy-D-Glucose (2-DG) in India.
The oral drug has been granted permission by the Drugs Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe Covid-19 patients.
MSN said it will be launching the drug under the brand name MSN 2D in sachet form as a twice a day product in strength of 2.34 g.
The drug comes in a powder form and has to be taken by dissolving in water. It works by accumulating in virus infected cells and prevents growth of the virus by stopping energy production and viral synthesis.
MSN said while it has already rolled out anti-viral medication like Oseltamivir capsules and anti-Covid drugs like Favipiravir and Baricitinib as well as antifungal drugs like Posaconazole in the fight against Covid-19, it is also conducting clinical trials for investigational drugs.
These include Aviptadil for which it is conducting clinical trials on severe hospitalized patients and with Molnupiravir on mild and moderate Covid-19 patients.
The oral drug has been granted permission by the Drugs Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe Covid-19 patients.
MSN said it will be launching the drug under the brand name MSN 2D in sachet form as a twice a day product in strength of 2.34 g.
The drug comes in a powder form and has to be taken by dissolving in water. It works by accumulating in virus infected cells and prevents growth of the virus by stopping energy production and viral synthesis.
MSN said while it has already rolled out anti-viral medication like Oseltamivir capsules and anti-Covid drugs like Favipiravir and Baricitinib as well as antifungal drugs like Posaconazole in the fight against Covid-19, it is also conducting clinical trials for investigational drugs.
These include Aviptadil for which it is conducting clinical trials on severe hospitalized patients and with Molnupiravir on mild and moderate Covid-19 patients.
[ad_2]
Source link
